Recent studies have indicated that certain classes of statins have effects beyond cholesterol reduction. They might protect against the risk of getting liver cancer. The new research has raised the eyebrows of many in the medical community. So now they’re asking what are the other impacts of statin therapy — not just on cardiovascular health.
Statins, both lipophilic (fat-soluble) and hydrophilic (water-soluble) varieties, are the most prescribed class of drugs to control cholesterol. Yet their possible benefits might go even further, into wholly different fields like liver disease care. There is evidence that statins can be effective in slowing the advancement of liver fibrosis. And they can even lower the risk of developing hepatocellular carcinoma, the most prevalent form of liver cancer.
The observational study included data from more than 16,000 patients. It uncovered that statin users had a 22% reduced risk of hepatic decompensation, a severe complication associated with liver conditions. The study’s results indicated that among statins with lipophilic profiles, they had a greater efficacy in preventing hepatic decompensation. Over a ten-year period, they demonstrated lower ten-year cumulative incidence of this condition compared to hydrophilic statins. More particularly, the ten-year cumulative incidence was 3.7% among lipophilic statin users compared with 4.1% among hydrophilic statin users.
Furthermore, cirrhotic patients on statins had lower rates of HCC and hepatic decompensation. The results for patients on the lipophilic statins compared to those on the hydrophilic statins were not very different. Yet across the ten-year study, the difference was only 0.4%.
These early outcomes are tremendously encouraging! It’s important to keep in mind that statins aren’t targeted therapies for liver cancer or its complications. The investigator, Dr. Patrick Kee, MD, PhD, underscored the fact that hepatocellular carcinoma (HCC) and hepatic decompensation were not the intended targets of statin therapy. It could offer one more even bigger potential boon to patients who are at risk of developing these liver diseases.
As a result, many physicians are afraid to use statin therapy because of perceived safety concerns. This concern is particularly common among patients with dyslipidemia and increased liver transaminases. Liver injury is a well-documented side effect of statins, often presenting as testosterone-catalyzed increases in liver enzymes AST and ALT. This calls into question their use in these vulnerable populations. Dr. Kee noted that clinicians need to weigh the risk against the benefit when deciding to start treatment.
“In patients with dyslipidemia and elevated liver enzymes, physicians often express concerns about the safety of initiating statin therapy for treating hyperlipidemia,” said Dr. Kee.
This population-based study provides important clinical information on the potential protective effects of statins against liver cancer. It does highlight the need for further studies to investigate this opportunity further. Dr. Wael Harb, MD agreed that the observational nature of the study was a limitation. He said that, “Although these findings cannot establish causation by themselves, they provide further evidence … [of] a burgeoning body of research, showing that statins may have effects that extend beyond lowering cholesterol.”
This calls for an in-depth investigation, which is very much needed. Now we need to determine which patient subgroups should receive statin therapy and more importantly, their expected benefits.
“More data is needed over time to define a statistically significant association or causation,” Dr. Harb added.
Dr. Jossef Amirian, MD, a board-certified cardiologist who was not involved in the study, explained that while statins primarily target cholesterol levels and reduce major adverse cardiac events (MACE), their role in managing liver disease is gaining attention. Here, he explained that lipophilic statins are able to halt the progression of fibrosis. This measure can further contribute to preventing the highest risk patients from eventually developing HCC.
“This study theorizes that statins, specifically lipophilic statins, may help to slow down the progression of fibrosis,” Dr. Amirian stated.
These trends reflect the protective effect of statins against the risk of liver cancer. We desperately lack the large, well-designed studies that can help us understand these effects more deeply.
“More research is also required to understand the particular benefits of lipophilic statins, including how they act on the body to decrease the risk of liver cancer,” Dr. Amirian added.
As researchers continue to explore this area, physicians remain cautious but optimistic about the implications of statin therapy for patients with liver conditions. Current findings provide a basis for further research. Specificity of these studies should aim to uncover the full slate of benefits that accompany statin use.
Leave a Reply